Inactive Instrument

Arix Bioscience plc

Equities

ARIX

GB00BD045071

Investment Management & Fund Operators

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc.. CI
RTW Biotech Opportunities NAV increases 2.5% in January AN
RTW Biotech Opportunities Completes Arix Bioscience Acquisition MT
Katoro Gold launches fundraising, eyes board shake-up AN
Arix Bioscience's Asset Sale to RTW Biotech Takes Effect MT
Arix Bioscience shares suspended ahead of RTW takeover AN
Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition MT
Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech MT
Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech MT
RTW Biotech completes Arix investment in takeover run-up AN
RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover MT
Arix Bioscience plc Announces Resignation of Directors CI
Arix Bioscience eyes USD19 million return from Harpoon sale AN
Arix Bioscience Flags Proceeds from Merck's Purchase of Harpoon Therapeutics MT
Rtw Biotech Opportunities Operating Ltd completed the acquisition of a 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million. CI
Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co. MT
Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. for $410 million. CI
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy MT
RTW Biotech Opportunities Ltd and RTW Investments, LP agreed to acquire Arix Biosciences Plc's assets from Arix Bioscience plc for £190 million. Herbert Smith Freehills LLP acted as legal advisor to RTW Biotech Opportunities Ltd and RTW Investments, LP. CI
FTSE 100 Closes Up 0.28% as Interest Rate Rise Fears Start to Ease DJ
RTW Biotech agrees "immediately accretive" Arix Bioscience takeover AN
RTW Biotech Opportunities, Arix Bioscience Agree on Potential Merger Terms MT
Rtw Biotech Opportunities Operating Ltd enter into an agreement to acquire 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million. CI
Transcript : RTW Biotech Opportunities Ltd, Arix Bioscience plc - Pre Recorded M&A Call
Gran Tierra completes offers, Pensana wins grant AN
Chart Arix Bioscience plc
More charts
Arix Bioscience plc is a United Kingdom-based global venture capital company. The Company is focused on investing in biotechnology companies to deliver superior risk-adjusted returns to shareholders. The Company is engaged in sourcing, financing, and developing healthcare and life science businesses globally. It focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company's core portfolio includes Artios Pharma Limited, Aura Biosciences, Inc., Disc Medicine Inc., Ensoma, Harpoon Therapeutics, Inc., Imara, Inc., and Iterum Therapeutics Limited. Its program includes AU-011, ART4215 + talazoparib, Bitopertin, HPN328, HPN217, ART0380, ART4215, and DISC-0974. It has approximately 11 clinical trials and is conducting nine pre-clinical studies. The Company's subsidiaries include Arix Bioscience Holdings Limited, Arix Bioscience, Inc, Arix Capital Management Limited, Arthurian Life Sciences GP Limited, and ALS SPV Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock Arix Bioscience plc - London S.E.
  4. News Arix Bioscience plc
  5. Arix Bioscience : To Invest $11 Million In Disc Medicine